Apolipoprotein A-IV for Glucose Tolerance Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperglycemia-related disorders, such as type 2 diabetes and prediabetes, are inadequate in effectively managing blood glucose levels and improving insulin secretion, leading to complications like renal failure, blindness, and heart disease.
Innovation Solution
Administration of apolipoprotein A-IV or its biologically active analogues, which contribute to post-prandial glucose tolerance, formulated as a pharmaceutical composition for systemic administration to restore normal glucose tolerance and lower blood glucose levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for hyperglycemia are used, then blood glucose levels are managed to some extent, but insulin secretion is not effectively improved and complications still occur
Solution Approach 1:
Apolipoprotein A-IV acts as a mediator substance that improves insulin secretion and glucose tolerance. The patent administers apoA-IV or its analogues as an intermediary agent to enhance the body's natural insulin response, thereby effectively managing blood glucose levels and preventing complications associated with hyperglycemia
2Reliability
If apolipoprotein A-IV is administered to restore glucose tolerance, then blood glucose levels are lowered and insulin secretion is improved, but the complexity of the treatment increases
Solution Approach 1:
The patent utilizes biologically active analogues of apolipoprotein A-IV that have at least 90% identity to the native protein. By modifying amino acid sequences while maintaining biological activity, the treatment achieves effective glucose tolerance restoration with potentially improved pharmacokinetic properties and reduced complexity in terms of production and administration
Data Source
AI summary
Methods for treating hyperglycemia disorders in a subject in need thereof and pharmaceutical compositions for the treatment of hyperglycemia disorders are disclosed. The methods include administering an effective amount of apolipoprotein A-IV to the subject. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject having hyperglycemic disorders, including insulin resistant disorders, such as prediabetes, metabolic syndrome, polycystic ovary disease, type A syndrome, gestational diabetes, and endocrine conditions associated with hyperglycemia, including Cushing's Disease, glucagon excess (glucagon secreting tumors) and acromegaly.